1. Scrip

Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

 
• By Jung Won Shin

Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds. 

Desperate businessmen
Janssen Drops Hanmi's GLP-1/GCG peptide As Glycemic Control Targets Unmet

Janssen Pharmaceutical Cos. has returned the rights to obesity/diabetes therapy HM12525A (JNJ-5111), a long-acting GLP/GCG analog to originator Hanmi Pharmaceutical Co. Ltd., after Phase II studies achieved their weight reduction targets, the primary evaluation indicator, but not their glycemic control goals for obese diabetics.

The South Korean firm was upbeat however. “Through the results of Phase II trials Janssen has conducted, the compound has sufficiently proven its efficacy as an obesity drug," it declared

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia